|Articles|August 1, 2009

ACT June 2009 BPA Statement

External Link - article-619124.pdf

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Global Breast Cancer Trials Show Progress in Diversity, But Gaps Remain

ByGen Li, PhD, MBA,Andy Studna, Senior Editor

October 23rd 2025

Bringing Clinical Trials Into the Digital Era with eConsent

ByVinita Navadgi

October 23rd 2025

ACT Brief: AI Innovations, Vision Trial Breakthroughs, and a Major Industry Acquisition

ByAndy Studna, Senior Editor

October 23rd 2025

© Pixel-Shot - © Pixel-Shot - stock.adobe.com

Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema

ByAndy Studna, Senior Editor

October 22nd 2025

A Look Back: AI and Pragmatic Trials Took Center Stage at SCOPE Summit 2025

ByRajneesh Patil,Drew Garty,Andy Studna, Senior Editor

October 22nd 2025

ACT June 2009 BPA Statement

Newsletter

Related Content

Global Breast Cancer Trials Show Progress in Diversity, But Gaps Remain

Bringing Clinical Trials Into the Digital Era with eConsent

ACT Brief: AI Innovations, Vision Trial Breakthroughs, and a Major Industry Acquisition

Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema

A Look Back: AI and Pragmatic Trials Took Center Stage at SCOPE Summit 2025

Trending on Applied Clinical Trials Online

Bringing Clinical Trials Into the Digital Era with eConsent

Global Breast Cancer Trials Show Progress in Diversity, But Gaps Remain

ACT Brief: AI Innovations, Vision Trial Breakthroughs, and a Major Industry Acquisition

Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema

ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer